Drug:
Reaction: NO ADVERSE EVENT
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26930269 |
US |
72 | 1 |
Off label use, Product dose omission issue, Device leakage, No adverse event, |
||||
OMALIZUMAB, |
||||
| 202 | 26930273 |
US |
2 | |
Product storage issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 203 | 26930754 |
US |
||
Device malfunction, No adverse event, Device malfunction, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 204 | 26921532 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
OMALIZUMAB, |
||||
| 205 | 26921576 |
US |
||
Drug ineffective, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 206 | 26921666 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 207 | 26922083 |
US |
1 | |
Off label use, Off label use, No adverse event, |
||||
MOSUNETUZUMAB, POLATUZUMAB VEDOTIN, |
||||
| 208 | 26922088 |
US |
39 | 2 |
Needle issue, No adverse event, Wrong technique in device usage process, |
||||
ABATACEPT, |
||||
| 209 | 26922107 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
EMICIZUMAB, |
||||
| 210 | 26922552 |
US |
1 | |
Product dose omission issue, Needle issue, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 211 | 26922566 |
US |
2 | |
Wrong technique in device usage process, Device defective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 212 | 26922600 |
US |
23 | 2 |
Product dose omission issue, No adverse event, |
||||
LANADELUMAB-FLYO, |
||||
| 213 | 26922688 |
US |
||
No adverse event, Device malfunction, Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 214 | 26922783 |
US |
||
Product communication issue, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 215 | 26922866 |
US |
||
Device malfunction, Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 216 | 26923097 |
US |
45 | 2 |
Product dose omission issue, No adverse event, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 217 | 26923169 |
US |
71 | |
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 218 | 26923182 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
EMICIZUMAB, |
||||
| 219 | 26923286 |
US |
1 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, SACUBITRIL AND VALSARTAN, |
||||
| 220 | 26923378 |
US |
32 | 1 |
Drug ineffective, No adverse event, |
||||
REMIBRUTINIB, OMALIZUMAB, |
||||
| 221 | 26923486 |
US |
||
Intercepted product storage error, No adverse event, |
||||
ALTEPLASE, |
||||
| 222 | 26923542 |
US |
56 | |
No adverse event, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 223 | 26923608 |
US |
||
Drug ineffective, No adverse event, |
||||
RANIBIZUMAB, |
||||
| 224 | 26924774 |
US |
||
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN PHOSPHATE, |
||||
| 225 | 26924791 |
US |
40 | 2 |
No adverse event, Treatment failure, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, METHOTREXATE, METHOTREXATE SODIUM, AZATHIOPRINE, AZATHIOPRINE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, CALCIUM, FOLIC ACID, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METHYLPREDNISOLONE, |
||||
| 226 | 26925017 |
US |
||
Drug ineffective, No adverse event, |
||||
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE, |
||||
| 227 | 26925933 |
US |
80 | 2 |
Product availability issue, No adverse event, |
||||
MESALAMINE, |
||||
| 228 | 26926185 |
US |
||
Product taste abnormal, Product physical issue, Product desiccant issue, Product size issue, Product coating issue, No adverse event, Poor quality product administered, Product container seal issue, |
||||
DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE, |
||||
| 229 | 26914720 |
US |
1 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 230 | 26914806 |
US |
||
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 231 | 26914870 |
US |
1 | |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 232 | 26914919 |
US |
2 | |
Product dose omission issue, Wrong technique in device usage process, Device defective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 233 | 26915512 |
US |
62 | 1 |
Incorrect dose administered, No adverse event, |
||||
OSELTAMIVIR PHOSPHATE, |
||||
| 234 | 26915526 |
US |
||
Drug ineffective, No adverse event, |
||||
OSELTAMIVIR PHOSPHATE, |
||||
| 235 | 26915664 |
US |
2 | |
Device issue, Wrong technique in device usage process, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 236 | 26915813 |
US |
28 | |
Incorrect dose administered by device, Device delivery system issue, Device deposit issue, Wrong technique in product usage process, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 237 | 26915819 |
US |
14 | 2 |
Off label use, No adverse event, |
||||
EMICIZUMAB, |
||||
| 238 | 26915851 |
US |
4 | |
Product storage issue, No adverse event, |
||||
| 239 | 26915871 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE, |
||||
| 240 | 26915962 |
US |
75 | |
Device difficult to use, Product quality issue, No adverse event, |
||||
| 241 | 26915998 |
US |
78 | |
Wrong technique in device usage process, Wrong technique in product usage process performed in error, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, CEPHALEXIN, BUPROPION, LISINOPRIL, CLONAZEPAM, |
||||
| 242 | 26916082 |
US |
52 | |
Drug dose omission by device, Wrong technique in product usage process, Device deposit issue, Device malfunction, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 243 | 26916097 |
US |
64 | 2 |
Product dose omission issue, No adverse event, |
||||
CLONAZEPAM, DICYCLOMINE HYDROCHLORIDE, CYANOCOBALAMIN, HYDROCHLOROTHIAZIDE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, CETIRIZINE HCL, CETIRIZINE, SUMATRIPTAN SUCCINATE, NEBIVOLOL HYDROCHLORIDE, NYSTATIN, BUPROPION HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, MONTELUKAST SODIUM, MONTELUKAST, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, ERGOCALCIFEROL, SERTRALINE HYDROCHLORIDE, |
||||
| 244 | 26916104 |
US |
64 | 2 |
Product storage error, Drug delivery system issue, No adverse event, |
||||
| 245 | 26916553 |
US |
2 | |
Product storage error, Product quality issue, No adverse event, |
||||
| 246 | 26916561 |
CA |
43 | 2 |
Breast cancer, Maternal exposure during pregnancy, Pain, Oedema peripheral, Nasopharyngitis, Infusion related reaction, Nail disorder, Musculoskeletal stiffness, Irritable bowel syndrome, Nausea, Lip dry, Injury, C-reactive protein abnormal, Obesity, Joint swelling, Gastrointestinal disorder, Oedema, Anti-cyclic citrullinated peptide antibody positive, Arthropathy, Malaise, Infection, Delirium, Joint range of motion decreased, Dyspnoea, Muscle injury, Alopecia, Muscle spasms, Osteoarthritis, Chest pain, Hand deformity, Memory impairment, Blood cholesterol increased, Abdominal discomfort, Drug hypersensitivity, General physical health deterioration, Hepatic enzyme increased, Lung disorder, Condition aggravated, Blister, Abdominal pain, Inflammation, Confusional state, Mobility decreased, Migraine, Decreased appetite, Ill-defined disorder, Arthralgia, Discomfort, Bursitis, Folliculitis, Asthenia, Myositis, Helicobacter infection, Musculoskeletal pain, Blepharospasm, No adverse event, Contusion, Fatigue, Lower respiratory tract infection, Night sweats, Off label use, Impaired healing, Adjustment disorder with depressed mood, Glossodynia, Back disorder, Amnesia, Duodenal ulcer perforation, Intentional product use issue, |
||||
CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CANDESARTAN, PREDNISONE, SARILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, CORTISONE ACETATE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, SULFASALAZINE, SULFASALAZINE, TOFACITINIB, TOFACITINIB CITRATE, ALENDRONATE SODIUM, ALENDRONATE SODIUM, LEFLUNOMIDE, LEFLUNOMIDE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, OXYCODONE, ALENDRONATE SODIUM, ALENDRONATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ADALIMUMAB-ADAZ, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 247 | 26916646 |
US |
2 | |
Off label use, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 248 | 26916690 |
US |
52 | 2 |
Off label use, No adverse event, |
||||
BEVACIZUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PEMBROLIZUMAB, |
||||
| 249 | 26916741 |
US |
2 | |
Product preparation error, No adverse event, |
||||
PERTUZUMAB, |
||||
| 250 | 26917482 |
US |
80 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 251 | 26917540 |
US |
||
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 252 | 26917580 |
US |
49 | 1 |
Product dose omission in error, No adverse event, |
||||
AVAPRITINIB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 253 | 26917927 |
64 | ||
Off label use, No adverse event, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 254 | 26918221 |
US |
2 | |
Intercepted product storage error, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 255 | 26918372 |
US |
2 | |
Maternal exposure during pregnancy, Off label use, No adverse event, |
||||
RISDIPLAM, |
||||
| 256 | 26918450 |
US |
1 | |
Radioisotope scan abnormal, No adverse event, |
||||
FLURPIRIDAZ F-18, NASAL, SODIUM CHLORIDE, SALINE, SALINE NASAL SPRAY, (SALINE), |
||||
| 257 | 26918456 |
PR |
||
Radioisotope scan abnormal, No adverse event, |
||||
TETROFOSMIN, TECHNETIUM TC-99M, |
||||
| 258 | 26918868 |
US |
20 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, EMICIZUMAB, |
||||
| 259 | 26919017 |
US |
||
Drug dose omission by device, No adverse event, |
||||
GLUCAGON, |
||||
| 260 | 26919897 |
30 | 1 | |
No adverse event, |
||||
NALTREXONE, |
||||
| 261 | 26919985 |
US |
||
Product storage issue, Product dose omission issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 262 | 26919987 |
US |
2 | |
Device defective, No adverse event, Product dose omission issue, |
||||
OMALIZUMAB, |
||||
| 263 | 26919990 |
US |
23 | 1 |
Underdose, Needle issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 264 | 26920005 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 265 | 26920008 |
US |
2 | |
Inappropriate schedule of product administration, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST, ROSUVASTATIN, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 266 | 26921027 |
US |
||
Product dose omission issue, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 267 | 26921221 |
PR |
||
Radioisotope scan abnormal, No adverse event, |
||||
TETROFOSMIN, TECHNETIUM TC-99M, |
||||
| 268 | 26921222 |
PR |
||
Radioisotope scan abnormal, No adverse event, |
||||
TETROFOSMIN, TECHNETIUM TC-99M, |
||||
| 269 | 26921224 |
PR |
||
Radioisotope scan abnormal, No adverse event, |
||||
TETROFOSMIN, TECHNETIUM TC-99M, |
||||
| 270 | 26921225 |
PR |
||
Radioisotope scan abnormal, No adverse event, |
||||
TETROFOSMIN, TECHNETIUM TC-99M, |
||||
| 271 | 26921239 |
US |
1 | |
Product dose omission issue, No adverse event, |
||||
SITAGLIPTIN PHOSPHATE, |
||||
| 272 | 26909501 |
CN |
73 | 1 |
No adverse event, |
||||
DEXAMETHASONE, BIMATOPROST, |
||||
| 273 | 26909552 |
US |
59 | 2 |
Off label use, No adverse event, |
||||
ROPEGINTERFERON ALFA-2B, |
||||
| 274 | 26909559 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 275 | 26909571 |
US |
||
Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 276 | 26909585 |
US |
2 | |
Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 277 | 26909682 |
US |
1 | |
Drug dose omission by device, Product use complaint, Device failure, Device malfunction, No adverse event, |
||||
LIRAGLUTIDE, LIRAGLUTIDE, |
||||
| 278 | 26909931 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
| 279 | 26909944 |
US |
||
Product use issue, No adverse event, |
||||
VORTIOXETINE, |
||||
| 280 | 26910186 |
US |
||
Maternal exposure via partner during pregnancy, No adverse event, |
||||
RESMETIROM, |
||||
| 281 | 26910363 |
US |
2 | |
Product delivery mechanism issue, Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 282 | 26910408 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 283 | 26910444 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 284 | 26910459 |
US |
74 | 1 |
No adverse event, |
||||
TIRZEPATIDE, |
||||
| 285 | 26910540 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 286 | 26910578 |
US |
||
Off label use, No adverse event, |
||||
OBINUTUZUMAB, OBINUTUZUMAB, OBINUTUZUMAB, |
||||
| 287 | 26910579 |
US |
||
Product use issue, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 288 | 26910599 |
US |
2 | |
Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 289 | 26910609 |
US |
||
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 290 | 26910641 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 291 | 26910642 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 292 | 26910684 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 293 | 26910732 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 294 | 26910734 |
EU |
19 | 2 |
Overdose, No adverse event, |
||||
LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, |
||||
| 295 | 26910763 |
JP |
2 | |
Product contamination physical, No adverse event, |
||||
ABATACEPT, |
||||
| 296 | 26910800 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 297 | 26910883 |
US |
66 | 1 |
Product delivery mechanism issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 298 | 26910929 |
US |
59 | |
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 299 | 26910952 |
US |
||
Recalled product administered, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 300 | 26910956 |
US |
2 | |
Product storage issue, Product availability issue, No adverse event, |
||||
OCRELIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30